GlobeNewswire 3/6 IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...
GlobeNewswire 3/5 IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
GlobeNewswire 3/5 Sandoz announces nominations to the Board of Directors and leadership change
GlobeNewswire 2/26 IO Biotech to Present at 44th Annual Cowen Health Care Conference
GlobeNewswire 2/7 Alleo Labs Announces Publication on the Use of Artificial Intelligence in Neuroscience Drug Discover...
TeleTrader 2/1 US opens higher, recovers from Wednesday's losses
TeleTrader 2/1 Merck's Q4 sales up 6% to $14.6B
TeleTrader 1/27 J&J, Merck CEOs to testify before Senate on drug prices
GlobeNewswire 1/9 C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted ...
GlobeNewswire 12/21/2023 IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
GlobeNewswire 12/7/2023 Compass Pathways appoints Teri Loxam as Chief Financial Officer
GlobeNewswire 12/4/2023 Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
GlobeNewswire 11/15/2023 Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies
GlobeNewswire 11/13/2023 IO Biotech Announces 2023 Third Quarter Results
GlobeNewswire 11/13/2023 Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire 11/10/2023 IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
GlobeNewswire 11/8/2023 IO Biotech Announces Participation in Upcoming Investor Conferences
GlobeNewswire 11/8/2023 AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for ...
GlobeNewswire 11/7/2023 Arbutus Announces CEO, William Collier, to Retire December 31, 2023
GlobeNewswire 11/6/2023 Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy...
GlobeNewswire 11/1/2023 IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Me...
GlobeNewswire 10/31/2023 Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combinat...
TeleTrader 10/26/2023 Merck's Q3 sales up 7% to $16B
Newsfile Corp 10/26/2023 Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694
TeleTrader 10/20/2023 Daiichi Sankyo, Merck announce collaboration on cancer drugs